Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE)

Chemico-Biological Interactions

Volumn 191, Issue 1-3, 2011, Pages 357-363

  Baba, Shahid P ^a   Hellmann, Jason ^a   Srivastava, Sanjay ^a   Bhatnagar, Aruni ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Advanced glycation end products; Advanced lipoxidation end products; Aldose reductase; RAGE

Indexed keywords

4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDEHYDE REDUCTASE; GLUCOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME REGULATION; EPIDIDYMIS FAT; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; LIPID MEMBRANE; LIPID PEROXIDATION; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STREPTOZOCIN DIABETES; UPREGULATION;

ACROLEIN; ADIPOSE TISSUE; ALDEHYDE REDUCTASE; ALDEHYDES; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIETARY FATS; EPIDIDYMIS; GENE DELETION; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY; MALE; MICE; OBESITY; OXIDATION-REDUCTION; RECEPTORS, IMMUNOLOGIC;

MURINAE; MUS;

EID: 79957578430     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2011.01.024     Document Type: Conference Paper

References (48)

1. M. Brownlee, Advanced protein glycosylation in diabetes and aging, Annu. Rev. Med. 46 (1995) 223-234.
2. R. Singh, A. Barden, T. Mori, L. Beilin, Advanced glycation end-products: a review, Diabetologia 44 (2) (2001) 129-146. (Pubitemid 32156196)
3. K. Horie, T. Miyata, K. Maeda, S. Miyata, S. Sugiyama, H. Sakai, C. van Ypersole de Strihou, V.M.Monnier, J.L. Witztum, K. Kurokawa, Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy, J. Clin. Invest. 100 (12) (1997) 2995-3004. (Pubitemid 28022836)
4. E.D. Schleicher, E. Wagner, A.G. Nerlich, Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging, J. Clin. Invest. 99 (3) (1997) 457-468.
5. J.H. Li, W. Wang, X.R. Huang, M. Oldfield, A.M. Schmidt, M.E. Cooper, H.Y. Lan, Advanced glycation end products induce tubular epithelial- myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway, Am. J. Pathol. 164 (4) (2004) 1389-1397.
6. S.F. Yan, R. Ramasamy, A.M. Schmidt, Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response, J. Mol. Med. 87 (3) (2009) 235-247.
7. M.P. Wautier, O. Chappey, S. Corda, D.M. Stern, A.M. Schmidt, J.L. Wautier, Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE, Am. J. Physiol. Endocrinol. Metab. 280 (5) (2001) E685-694.
8. E. Harja, D.X. Bu, B.I. Hudson, J.S. Chang, X. Shen, K. Hallam, A.Z. Kalea, Y. Lu, R.H. Rosario, S. Oruganti, Z. Nikolla, D. Belov, E. Lalla, R. Ramasamy, S.F. Yan, A.M. Schmidt, Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice, J. Clin. Invest. 118 (1) (2008) 183-194.
9. S.P. Baba, O.A. Barski, Y. Ahmed, T.E. O'Toole, D.J. Conklin, A. Bhatnagar, S. Srivastava, Reductive metabolism of AGE precursors: ametabolic route for preventing AGE accumulation in cardiovascular tissue, Diabetes 58 (11) (2009) 2486-2497.
10. S. Srivastava, K.V. Ramana, R. Tammali, S.K. Srivastava, A. Bhatnagar, Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells, Diabetes 55 (4) (2006) 901-910. (Pubitemid 44100162)
11. D.J. Conklin, P. Haberzettl, R.A. Prough, A. Bhatnagar, Glutathione-S-transferase P protects against endothelial dysfunction induced by exposure to tobacco smoke, Am. J. Physiol. Heart Circ. Physiol. 296 (5) (2009) H1586-1597.
12. L. Park, K.G. Raman, K.J. Lee, Y. Lu, L.J. Ferran Jr., W.S. Chow, D. Stern, A.M. Schmidt, Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts, Nat. Med. 4 (9) (1998) 1025-1031.
13. E.A. Friedman, Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications, Diabetes Care 22 (Suppl. 2) (1999) B65-71.
14. D.R. Sell, V.M. Monnier, Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process, J. Biol. Chem. 264 (36) (1989) 21597-21602. (Pubitemid 20028722)
15. Z. Makita, S. Radoff, E.J. Rayfield, Z. Yang, E. Skolnik, V. Delaney, E.A. Friedman, A. Cerami, H. Vlassara, Advanced glycosylation end products in patients with diabetic nephropathy, N. Engl. J. Med. 325 (12) (1991) 836-842.
16. R. Bucala, Z. Makita, T. Koschinsky, A. Cerami, H. Vlassara, Lipid advanced glycosylation: pathway for lipid oxidation in vivo, Proc. Natl. Acad. Sci. U.S.A. 90 (14) (1993) 6434-6438. (Pubitemid 23207227)
17. Z. Makita, H. Vlassara, A. Cerami, R. Bucala, Immunochemical detection of advanced glycosylation end products in vivo, J. Biol. Chem. 267 (8) (1992) 5133-5138.
18. H.P. Hammes, S. Martin, K. Federlin, K. Geisen, M. Brownlee, Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy, Proc. Natl. Acad. Sci. U.S.A. 88 (24) (1991) 11555-11558. (Pubitemid 21916080)
19. F. Hayase, R.H. Nagaraj, S. Miyata, F.G. Njoroge, V.M. Monnier, Aging of proteins: immunological detection of a glucose-derived pyrrole formed during maillard reaction in vivo, J. Biol. Chem. 264 (7) (1989) 3758-3764.
20. W. Palinski, T. Koschinsky, S.W. Butler, E. Miller, H. Vlassara, A. Cerami, J.L. Witztum, Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits, Arterioscler. Thromb. Vasc. Biol. 15 (5) (1995) 571-582.
21. S. Hummasti, G.S. Hotamisligil, Endoplasmic reticulum stress and inflammation in obesity and diabetes, Circ. Res. 107 (5) (2010) 579-591.
22. G. Solinas, M. Karin, JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction, FASEB J. 24 (8) (2010) 2596-2611.
23. H. Shi, M.V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, J.S. Flier, TLR4 links innate immunity and fatty acid-induced insulin resistance, J. Clin. Invest. 116 (11) (2006) 3015-3025.
24. F. Kim, M. Pham, I. Luttrell, D.D. Bannerman, J. Tupper, J. Thaler, T.R. Hawn, E.W. Raines, M.W. Schwartz, Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity, Circ. Res. 100 (11) (2007) 1589-1596.
25. K. Uchida, Current status of acrolein as a lipid peroxidation product, Trends Cardiovasc. Med. 9 (5) (1999) 109-113.
26. M.M. Anderson, S.L. Hazen, F.F. Hsu, J.W. Heinecke, Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation, J. Clin. Invest. 99 (3) (1997) 424-432.
27. R. Kato, C. Mori, K. Kitazato, S. Arata, T. Obama, M. Mori, K. Takahashi, T. Aiuchi, T. Takano, H. Itabe, Transient increase in plasma oxidized LDL during the progression of atherosclerosis in apolipoprotein E knockout mice, Arterioscler. Thromb. Vasc. Biol. 29 (1) (2009) 33-39.
28. B. Shao, X. Fu, T.O. McDonald, P.S. Green, K. Uchida, K.D. O'Brien, J.F. Oram, J.W. Heinecke, Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I, J. Biol. Chem. 280 (43) (2005) 36386-36396.
29. J.R. Williamson, K. Chang, R.G. Tilton, C. Prater, J.R. Jeffrey, C. Weigel, W.R. Sherman, D.M. Eades, C. Kilo, Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration, Diabetes 36 (7) (1987) 813-821. (Pubitemid 17145302)
30. M.L. McCaleb, J. Sredy, J. Millen, D.M. Ackerman, D. Dvornik, Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat, J. Diabetes Complicat. 2 (1) (1988) 16-18.
31. N. Bank, P. Mower, H.S. Aynedjian, B.M. Wilkes, S. Silverman, Sorbinil prevents glomerular hyperperfusion in diabetic rats, Am. J. Physiol. 256 (6 Pt 2) (1989) F1000-1006.
32. W.P. Chang, E. Dimitriadis, T. Allen, M.E. Dunlop, M. Cooper, R.G. Larkins, The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus, Diabetologia 34 (4) (1991) 225-231.
33. R.G. Tilton, K. Chang, G. Pugliese, D.M. Eades, M.A. Province, W.R. Sherman, C. Kilo, J.R. Williamson, Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors, Diabetes 38 (10) (1989) 1258-1270. (Pubitemid 19247421)
34. S. Goldfarb, F.N. Ziyadeh, E.F. Kern, D.A. Simmons, Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats, Diabetes 40 (4) (1991) 465-471.
35. S.M. Donnelly, X.P. Zhou, J.T. Huang, C.I. Whiteside, Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat, Biochem. Cell Biol. 74 (3) (1996) 355-362.
36. S.M. Mauer, M.W. Steffes, S. Azar, D.M. Brown, Effects of sorbinil on glomerular structure and function in long-term-diabetic rats, Diabetes 38 (7) (1989) 839-846. (Pubitemid 20022388)
37. A.S. Reddi, G.N. Jyothirmayi, Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats, J. Diabetes Complicat. 7 (4) (1993) 233-240. (Pubitemid 24010427)
38. T.S. Kern, R.L. Engerman, Aldose reductase and the development of renal disease in diabetic dogs, J. Diabetes Complicat. 13 (1) (1999) 10-16. (Pubitemid 29195641)
39. N. Passariello, J. Sepe, G. Marrazzo, A. De Cicco, A. Peluso, M.C. Pisano, S. Sgambato, P. Tesauro, F. D'Onofrio, Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy, Diabetes Care 16 (5) (1993) 789-795. (Pubitemid 23127187)
40. M.M. Pedersen, J.S. Christiansen, C.E. Mogensen, Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition, Diabetes 40 (5) (1991) 527-531.
41. S. Srivastava, T.M. Harter, A. Chandra, A. Bhatnagar, S.K. Srivastava, J.M. Petrash, Kinetic studies of FR-1, a growth factor-inducible aldo-keto reductase, Bio-chemistry 37 (37) (1998) 12909-12917.
42. D.P. Ng, C.L. Hardy, W.C. Burns, E.E. Muggli, N. Kerr, J. McCausland, D. Alcorn, T.E. Adams, J.D. Zajac, R.G. Larkins, M.E. Dunlop, Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase, Endocrine 18 (1) (2002) 47-56. (Pubitemid 34828108)
43. M. Dunlop, Aldose reductase and the role of the polyol pathway in diabetic nephropathy, Kidney Int. Suppl. 77 (2000) S3-12.
44. S.F. Yan, R. Ramasamy, A.M. Schmidt, The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature, Circ. Res. 106 (5) (2010) 842-853.
45. V. Somoza, M. Lindenmeier, T. Hofmann, O. Frank, H.F. Erbersdobler, J.W. Baynes, S.R. Thorpe, A. Heidland, H. Zill, S. Bek, J. Huber, T. Weigle, S. Scheidler, A.E. Busch, K. Sebekova, Dietary bread crust advanced glycation end products bind to the receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral administration to healthy and subtotally nephrectomized rats, Ann. N.Y. Acad. Sci. 1043 (2005) 492-500. (Pubitemid 41123938)
46. T. Kislinger, N. Tanji, T. Wendt, W. Qu, Y. Lu, L.J. Ferran Jr., A. Taguchi, K. Olson, L. Bucciarelli, M. Goova, M.A. Hofmann, G. Cataldegirmen, V. D'Agati, M. Pischetsrieder, D.M. Stern, A.M. Schmidt, Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice, Arterioscler. Thromb. Vasc. Biol. 21 (6) (2001) 905-910. (Pubitemid 34168644)
47. N. Reiniger, K. Lau, D. McCalla, B. Eby, B. Cheng, Y. Lu, W. Qu, N. Quadri, R. Ananthakrishnan, M. Furmansky, R. Rosario, F. Song, V. Rai, A. Weinberg, R. Friedman, R. Ramasamy, V. D'Agati, A.M. Schmidt, Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse, Diabetes 59 (8) (2010) 2043-2054.
48. A.L. Tan, K.C. Sourris, B.E. Harcourt, V. Thallas-Bonke, S. Penfold, S. Andrikopoulos, M.C. Thomas, R.C. O'Brien, A. Bierhaus, M.E. Cooper, J.M. Forbes, M.T. Coughlan, Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy, Am. J. Physiol. Renal Physiol. 298 (3) (2010) F763-770.